PTK2 and thyroid cancer: As expected, these cells successfully knocked out FAK protein (p<0.0001) and well-characterized phosphorylation sites, including the Y397 autophosphorylation site, the Src-dependent Y925 site, and S910, which is a MAPK-dependent site (Figure 1A; Supplementary Figure 1A). Consistent with our previously published data using shRNA to knockdown FAK, FAK-KO decreased thyroid cancer adherent growth by 55% (Figure 1B, not significant) and nearly ablated anchorage independent growth by 25-fold (p < 0.01) (35) (Figure 1C).